Candriam S.C.A. Arcellx, Inc. Transaction History

Candriam S.C.A.

$16.9 Billion
Q4 2024

A detailed history of Candriam S.C.A. transactions in Arcellx, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 194,996 shares of ACLX stock, worth $12.3 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

194,996

Previous 240,363 18.87%

Holding current value

$12.3 Million

Previous $20.1 Million 26.02%

% of portfolio

0.09%

Previous 0.12%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	SELL	$75.39 - $106.53 $3.42 Million - $4.83 Million	-45,367 Reduced 18.87%	194,996 $14.9 Million
Q3 2024 Nov 13, 2024	BUY	$50.91 - $86.61 $1.19 Million - $2.02 Million	23,355 Added 10.76%	240,363 $20.1 Million
Q2 2024 Aug 05, 2024	SELL	$49.74 - $66.98 $149,220 - $200,940	-3,000 Reduced 1.36%	217,008 $12 Million
Q1 2024 May 03, 2024	SELL	$51.85 - $73.49 $3.21 Million - $4.56 Million	-62,005 Reduced 21.99%	220,008 $15.3 Million
Q4 2023 Feb 14, 2024	SELL	$31.75 - $57.99 $3.68 Million - $6.73 Million	-116,007 Reduced 29.15%	282,013 $15.7 Million
Q2 2023 Aug 08, 2023	SELL	$27.49 - $46.9 $1.35 Million - $2.3 Million	-49,134 Reduced 10.99%	398,020 $12.6 Million
Q1 2023 May 12, 2023	BUY	$26.92 - $33.94 $673,000 - $848,500	25,000 Added 5.92%	447,154 $13.8 Million
Q4 2022 Feb 13, 2023	BUY	$17.18 - $33.0 $6.68 Million - $12.8 Million	388,931 Added 1170.67%	422,154 $13.1 Million
Q3 2022 Nov 10, 2022	BUY	$16.67 - $22.04 $553,827 - $732,234	33,223 New	33,223 $624,000

Others Institutions Holding ACLX

# of Institutions

222

Shares Held

45.2M

Call Options Held

2.23M

Put Options Held

907K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $2.77B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account